Evidence map›Paper›PMID 42776333›Full record

ArticleNeurochemical research2026

DNA Topoisomerase IIβ Suppresses Microglial Inflammatory Cytokine Release: A Potential Regulator of Neuroinflammation.

Rama Şeyhali Abutayeh, Rümeysa Akbayır, Naki Burak Akül, Melike Cansel Eren, Timuçin Avşar, Yeşim Neğiş, Berçem Yeman-Kıyak, Sevim Işık

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rama Şeyhali AbutayehGraduate School of Sciences, Üsküdar University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-0905-1598
Rümeysa AkbayırGraduate School of Sciences, Üsküdar University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-3928-4966
Naki Burak AkülGraduate School of Sciences, Üsküdar University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-6628-338X
Melike Cansel ErenGraduate School of Health Science, Üsküdar University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-8629-6145
Timuçin AvşarDepartment of Medical Biology, School of Medicine, Bahçesehir University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-8841-4811
Yeşim NeğişDepartment of Medical Biochemistry, School of Medicine, Bahçesehir University, Istanbul, Turkey.ORCID http://orcid.org/0009-0007-2311-8166
Berçem Yeman-KıyakStem Cell Research and Application Center (ÜSKÖKMER), Üsküdar University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-9667-3506
Sevim IşıkGraduate School of Sciences, Üsküdar University, Istanbul, Turkey. sevim.isik@uskudar.edu.tr.ORCID http://orcid.org/0000-0001-7687-6082

Funding

Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 219S842
6 · The paper itself

Abstract

DNA topoisomerase IIβ (topo IIβ) is a nuclear enzyme that regulates DNA topology and gene expression, especially in post-mitotic cells such as neurons. Although its roles in neural development and transcriptional control are well-established, its involvement in neuroinflammatory processes is still to be investigated. This study aims to investigate whether topo IIβ modulates inflammatory responses in human microglial HMC3 cells under immune-stimulated conditions, considering that microglial cells are pivotal mediators of neuroinflammation in the central nervous system (CNS). Inflammation was induced using lipopolysaccharide (LPS), interferon-gamma (IFNγ), Adenosine triphosphate (ATP), whereas topo IIβ expression was modulated by overexpression and siRNA-mediated silencing. Western blot analysis demonstrated that LPS, IFNγ, and ATP stimulation did not alter the endogenous topo IIβ protein levels, indicating that its protein levels are stable under inflammatory conditions. Analysis of cytokine release indicated that topo IIβ overexpression decreased the release of key proinflammatory cytokines, suggesting an anti-inflammatory role. Conversely, the silencing of topo IIβ resulted in increased cytokine release, suggesting that topo IIβ typically functions to mitigate microglial inflammatory responses. Significantly, treatment with Lipofectamine™ 3000 alone increased cytokine release, indicating an intrinsic immunostimulatory impact of the transfection reagent. Collectively, these findings reveal an unacknowledged function of topo IIβ in attenuating neuroinflammatory signaling in microglia and underscore the necessity for careful interpretation of cytokine data when transfection reagents are present. Topo IIβ may represent a novel therapeutic target for modulating microglial activation in neuroinflammatory diseases.

Indexed as

CytokinesDNA-Binding ProteinsDNA Topoisomerases, Type IIMicrogliaNeuroinflammatory DiseasesPoly-ADP-Ribose Binding ProteinsCell LineHumansInflammationInterferon-gammaLipopolysaccharidesCytokinesDNA-Binding ProteinsDNA Topoisomerases, Type IIInterferon-gammaLipopolysaccharidesPoly-ADP-Ribose Binding ProteinsTOP2B protein, humanDNA topoisomerase IIβHMC3IFNγLipofectamineLPSMicrogliaNeuroinflammation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.